Moreover, we analyzed the predictive roles in prognosis with combined CCL19 and CCL21 in HCC and observed that high expression of CCL19 and CCL21 predicts a good prognosis in liver cancer from the TCGA database (Figure S5A), suggesting that combined CCL19 and CCL21 may be used as a new strategy for HCC immunotherapy. The gene discussed is CCL19; the disease is hepatocellular carcinoma.